[The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].

Autor:	Dobrynina LA; Research Center of Neurology, Moscow, Russia., Gubanova MV; Research Center of Neurology, Moscow, Russia., Belopasova AV; Research Center of Neurology, Moscow, Russia., Baydina EV; Research Center of Neurology, Moscow, Russia., Afanasev MA; Research Center of Neurology, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (2), pp. 74-80.
DOI:	10.17116/jnevro202212202174
Abstrakt:	Objective: To assess the effectiveness and safety of Erenumab, a monoclonal antibody to calcitonin gene-related peptide receptors, in patients with high-frequency episodic migraine (HFEM) in real-life study. Material and Methods: 35 patients with HFEM without aura (≥8-14 attacks per month) (30 females, mean age 32.4±8.1) received monthly subcutaneous administration of Erenumab 70 mg for 3 months. The primary endpoint was the change in monthly migraine days (MMDs) from baseline, the secondary endpoint was the proportion of patients who achieved a 50% reduction in the number of days with headache. The change in pain intensity, change in the number of days of use of acute migraine-specific medication, the effect on daily activity (HIT-6 scale, MIDAS), anxiety and depression (the Hospital Anxiety and Depression Scale) were assessed. Results: At the end of the third month Erenumab decreased MMDs by 5±3.6 ( p =0.00000). A 50% reduction in the mean number of migraine days per month was achieved for 60% of patients, the intensity of headache according to the visual analogue scale from 8±1.2 points to 5±2 points ( p =0.00000), monthly analgesics intake passed from 11±7 to 4.5±3.7 ( p =0.000001). 25.7% of patients did not respond to treatment, showing less than a 30% decrease in the number of days with headache. A decrease in pain intensity correlated with a decrease in anxiety (from 8±4 to 6±4 points ( p =0.003)) and depression (from 6±4 to 4±3 points ( p =0.0004)) according to HADS, reduced HIT-6 scale from 65±6 to 55±7 points ( p =0.00000) and MIDAS from 45 [33; 67] points to 16 [5; 33] ( p =0.000004)). Patients reported good tolerability of Erenumab. 25.7% of patients noted a tendency to constipation. No patient discontinued treatment due to adverse events. Conclusion: Real-life study confirmed the efficacy and safety of Erenumab in the treatment of HFEM, a decrease in the severity of comorbid anxiety and depression, and social maladjustment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu